Abris Capital Partners, a specialist private equity investor focused on the ESG transformation, has supported Scanmed, a Polish healthcare business, in acquiring Ars Medical, a specialist in cancer care treatment in Poland.
Abris Capital Partners (Abris), a specialist private equity investor focused on the ESG transformation, has supported Scanmed, a Polish healthcare business, in acquiring Ars Medical, a specialist in cancer care treatment in Poland.
Ars Medical specialises in oncology, haematology, cardiology, internal medicine and palliative care, as well as general and specialist outpatient care. The company is one of the leading local players in cancer care treatment, diagnostic imaging and commercial procedures, and has a team of 400 doctors and nurses, including over 100 specialists in 48 therapeutic areas.
The acquisition has strong strategic rationale, broadening Scanmed’s offer to accommodate the needs of its clients and strengthening its position as a private in-patient healthcare provider. Additionally, the acquisition will enable synergies with existing Scanmed facilities and expand the company’s presence in north-west Poland.
Abris acquired Scanmed in 2020 with a plan to build a local healthcare champion by improving and growing the group’s service offering in key therapeutic areas including cardiology, oncology, orthopaedics and ophthalmology, and expand its countrywide geographic coverage.
Abris’ previous investments in the healthcare sector include Matexlab, a Swiss vendor of innovative aesthetic medicine products, and Dentotal Protect, the leading distributor of dental consumables, instruments and equipment in Romania and Bulgaria.
